沙特队列中地舒单抗治疗骨质疏松后低钙血症的发生率与危险因素
该回顾性研究纳入303例接受地舒单抗治疗的沙特骨质疏松成人,发现21.1%发生低钙血症,其中71.9%为轻度、73.4%无症状。利尿剂使用是显著预测因素(aOR 3.44,p=0.008),维生素D缺乏与重度低钙血症相关。
要点
- 地舒单抗相关低钙血症发生率21.1%,多数为轻度且无症状。
- 利尿剂使用是低钙血症的显著预测因素(aOR 3.44,p=0.008)。
- 维生素D缺乏与重度低钙血症相关,需个体化监测。
核心结论
- 地舒单抗治疗后低钙血症在真实世界中常见,尤其见于使用利尿剂或维生素D水平低的患者。
研究设计与样本
- 回顾性分析,在三级医院纳入303例接受地舒单抗治疗的沙特骨质疏松成人。
主要发现
- 21.1%的患者发生低钙血症,其中71.9%为轻度(1级)低钙血症。
- 73.4%的低钙血症病例无症状,少数报告刺痛和肌肉酸痛。
- 利尿剂使用是显著预测因素(aOR 3.44,p=0.008)。
- 维生素D缺乏与重度(3级)低钙血症强烈相关。
关键数值与推荐
- 低钙血症发生率21.1%,轻度占71.9%,无症状占73.4%。
- 利尿剂使用预测低钙血症的aOR为3.44(p=0.008)。
临床怎么用
- 治疗前应综合评估风险,对使用利尿剂或维生素D缺乏者加强监测。
- 即使按标准补充钙和维生素D,仍需个体化监测低钙血症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Denosumab-associated hypocalcemia is common in real-world settings. In this Saudi cohort, 21.1% developed hypocalcemia, with diuretic use and vitamin D deficiency as key predictors. Findings highlight that individualized risk assessment and monitoring may enhance the safety of osteoporosis treatment. BACKGROUND: Denosumab, a widely used antiresorptive agent for osteoporosis, has demonstrated significant benefits in reducing fracture risk. However, hypocalcemia is a recognized adverse effect, with real-world data suggesting higher incidence rates than those reported in clinical trials. This study explores the incidence, severity, and predictors of denosumab-associated hypocalcemia in a Saudi cohort. METHODS: A retrospective analysis was conducted at a tertiary care hospital, involving 303 Saudi adults with osteoporosis who received denosumab. The study evaluated changes in calcium levels, incidence of hypocalcemia, and potential risk factors, including vitamin D status, renal function, and medication use. Multivariate logistic regression identified predictors of hypocalcemia. RESULTS: Hypocalcemia occurred in 21.1% of patients, with 71.9% experiencing mild (grade 1) hypocalcemia. Most cases were asymptomatic (73.4%), with tingling and muscle aches reported in a minority of patients. Diuretic use emerged as a significant predictor (aOR 3.44, p = 0.008). Vitamin D deficiency was strongly associated with severe hypocalcemia (grade 3). Despite adherence to standard calcium and vitamin D supplementation, a substantial proportion of patients developed hypocalcemia, underscoring the need for individualized monitoring. CONCLUSION: Hypocalcemia following denosumab is common in real-world practice, particularly in patients on diuretics or with low vitamin D levels. Clinicians should consider comprehensive pre-treatment risk assessment and tailored monitoring strategies to mitigate adverse outcomes in osteoporosis management.
引用
- Prabahar K, Alharthi NM, AlKenani R, et al. Hypocalcemia following denosumab in osteoporosis: Incidence and risk factors in a Saudi cohort. Osteoporos Int. 2026. PMID: 41615438. doi:10.1007/s00198-026-07862-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。